Valuation: Mateon Therapeutics Inc

Market Cap 96.08L 85.37L 79.67L 72.62L 1.37Cr 92Cr 1.38Cr 9.64Cr 3.74Cr 47Cr 3.61Cr 3.53Cr 151.54Cr P/E 2024
-3.13x
P/E 2025 0.13x
Enterprise Value 2.34Cr 2.08Cr 1.94Cr 1.77Cr 3.34Cr 225.25Cr 3.37Cr 24Cr 9.11Cr 115.15Cr 8.8Cr 8.61Cr 369.56Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
56.48%
Yield 2024 *
-
Yield 2025 -
14/08 Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
03/08 Oncotelic Therapeutics, Inc. announced that it has received $0.157001 million in funding from Pacific Pier Capital Ii, Llc CI
23/07 Oncotelic Therapeutics, Inc. announced that it has received $0.71184 million in funding CI
10/07 Oncotelic Therapeutics, Inc. announced that it expects to receive $0.71184 million in funding CI
07/07 Oncotelic Therapeutics, Inc. and Sapu Nano (Us) LLC Advance Joint Clinical Program and Expand European Clinical Sites CI
29/06 Oncotelic Therapeutics, Inc. and Sapu Nano Announce Peer-Reviewed Validation of Deciparticle Platform Supporting Clinical Development of Sapu003 CI
23/06 Oncotelic Therapeutics, Inc. announced that it has received $0.157001 million in funding from Pacific Pier Capital Ii, Llc CI
19/06 Oncotelic Therapeutics, Inc. Launches AI-Powered GMP Manufacturing Services Platform At BIO International Convention 2026 CI
17/06 Oncotelic Therapeutics, Inc. And TechForce Robotics, Inc. Advance AI-Powered GMP Manufacturing Services Platform For Revenue-Generating AI And Robotics Manufacturing Services CI
17/06 TechForce Robotics Advances Phase 2 Deployment Of PUR-E Autonomous Clean Room Support Robot At SAPU Bio OEB-5 Sterile Injectable cGMP Facility CI
08/06 Oncotelic Therapeutics, Inc. Showcases Pdaoai Capability in Advancing Drug Development CI
15/05 Oncotelic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
13/05 Sapu Nano And Oncotelic Therapeutics, Inc. Announce First Patient Dosed In Phase 1b Trial Of Sapu003, An Intravenous Deciparticle Formulation Of Everolimus CI
Manager TitleAgeSince
Chief Executive Officer 61 22/04/2019
Director of Finance/CFO 59 01/07/2019
Chief Tech/Sci/R&D Officer 77 06/01/2020
Director TitleAgeSince
Chairman 61 22/04/2019
Director/Board Member 61 11/05/2020
Director/Board Member 61 11/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
+4.16%+3.04%+49.37%+94.17% 7.42TCr
-3.11%-3.53%+20.19%+81.44% 5.74TCr
+0.89%-0.63%+2.17%+36.19% 4.76TCr
+0.36%+0.81%+342.39%+742.40% 4.43TCr
-0.96%-4.50%+24.96%+35.38% 4.25TCr
-0.20%-0.77%+4.13%+105.50% 4.07TCr
-0.54%+2.93%+9.31%+50.41% 3.1TCr
-2.68%+2.92%+29.33%+22.72% 2.85TCr
+0.05%-1.64%-8.14%-11.37% 2.43TCr
Average -0.23%-0.59%+52.63%+128.54% 4.34TCr
Weighted average by Cap. +0.12%-0.84%+56.96%+138.26%

Financials

2024 2025
Net sales - -
Net income -45.24L -40.2L -37.52L -34.19L -64.49L -43Cr -65.09L -4.54Cr -1.76Cr -22Cr -1.7Cr -1.66Cr -71Cr 25Cr 22Cr 21Cr 19Cr 36Cr 2.4TCr 36Cr 250.17Cr 97Cr 1.23TCr 94Cr 92Cr 3.93TCr
Net Debt 1.3Cr 1.16Cr 1.08Cr 98.28L 1.85Cr 124.99Cr 1.87Cr 13Cr 5.06Cr 64Cr 4.88Cr 4.78Cr 205.07Cr 1.38Cr 1.23Cr 1.15Cr 1.04Cr 1.97Cr 132.89Cr 1.99Cr 14Cr 5.38Cr 68Cr 5.19Cr 5.08Cr 218.03Cr
Logo Mateon Therapeutics Inc
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small-molecule injectable drugs for the treatment of cancer. The Company has three primary drugs and AI technology programs: AL-101 - Intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P- a vascular disrupting agent (VDA) - in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503- a second generation VDA - for the treatment of liquid tumors with focus on childhood leukemia; OT-101 - an antisense against TGF-b2-for the treatment of various cancers and for the treatment of various viruses, and Artemisinin-a natural derivative from an Asian herb Artemisia Annua.
Employees
-